Lumida
/PCVX
⌘K
Vaxcyte Inc

Vaxcyte Inc

PCVX
$59.47USD↑+0.97%+0.57 today

MARKET CAP

8.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$58 – $60

52W RANGE

$31
$65

AI Summary

Stalk
Sell NowMedium

PCVX is exhibiting a bearish pivot breakdown in a Stage 4 downtrend, with the recent failure to reclaim the 9 and 20 EMAs signaling a shift toward structural repair. Medium-term bias remains bearish, reinforced by price below the 50 SMA and the active Bearish Pivot Point pattern. Short-term rejection at the 9/20 EMA resistance zone confirms that timing favors selling into rallies. Selling now into the 59.99–60.10 zone aligns with the Momentum + EPS strategy’s preference for participating in momentum breakdowns.

  • ↑Vax31 may boost serotype coverage 45%, capturing market share
  • ↑$3.13B cash runway underwrites R&D and ops through 2025
  • ↓R&D expenses forecasted at $480M in 2025, pressuring cash
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

VaxSight, Inc. (NASDAQ:VACC) is a biopharmaceutical company specializing in the development and commercialization of innovative pneumococcal conjugate vaccines (PCVs) aimed at eradicating bacterial infections. With lead candidates Vax24 and Vax31, the company seeks to address significant unmet medical needs primarily within the adult and pediatric populations. VaxSight is strategically positioned in a growing market, focusing on broader serotype coverage to combat antibiotic resistance and evolving health challenges, thereby enhancing public health globally.

Bull says

  • ↑Vax31 may boost serotype coverage 45%, capturing market share
  • ↑$3.13B cash runway underwrites R&D and ops through 2025
  • ↑Adult PCV market ~$2B, poised for ~40% five-year growth
  • ↑High institutional ownership signals strong investor confidence
  • ↑Phase II shows superior immune responses, aiding FDA approval
  • ↑Positive momentum factors reflect improving stock sentiment

Bear says

  • ↓R&D expenses forecasted at $480M in 2025, pressuring cash
  • ↓No current revenue—weak growth and profitability factors
  • ↓FDA Phase III non-inferiority failure risks stall approval
  • ↓Pfizer/Merck dominance raises differentiation and pricing risk
  • ↓Rising leverage risk amid high spending may strain balance sheet
  • ↓Earnings yield concerns suggest potential overvaluation

Investment themes with PCVX

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2021 · Mgmt. Guidance

Updated 08-19-2026bullish

Transcript signals

Bull points

  • Our PCV franchise is intended to improve upon existing vaccines by covering the serotypes responsible for most of the remaining pneumococcal disease currently in circulation, while maintaining an immunogenicity profile comparable to, if not better than, Prevnar.
  • With our novel technology, we believe we can go beyond traditional vaccine approaches, as well as some new technologies like mRNA when it comes to addressing bacterial diseases.
  • With the Vax24 Phase 1-2 clinical study now underway, we expect to announce the top-line safety, tolerability, and immunogenicity results by the end of the year.

Bear points

  • As we look forward, we expect a substantial increase in 2022 expenses over full year and Q4 2021 annualized levels, particularly in R&D.
Read full transcript analysis ›